welcome to DuchenneXchange- a positively charged Duchenne muscular dystrophy community.
- join today!
Quantitative Muscle Ultrasound as a Marker of Progression in Children With Muscular Diseases
study id #: NCT03786913
condition: Inflammatory Myopathy, Duchenne Muscular Dystrophy
The aim of our study is to Assess skeletal muscle structural status in children with inflammatory myositis and Duchenne muscular dystrophy using musculoskeletal ultrasound and to perform a longitudinal follow up of these changes over 2 years and to assess the relation between these findings with clinical parameters, functional scales, biochemical and electromyographic tests.
mechanism of action: No pharmaceutical intervention
last updated: February 15, 2019
start date: March 8, 2016
estimated completion: February 2, 2019
size / enrollment: 48
This study will be carried out on two groups:
Group (I): fifty children diagnosed to have duchenne muscular dystrophy and inflammatory myositis.
Group (II): including 20 healthy children matching age and sex as control group.
patients will be subjected to
(A) Clinical evaluation
• Complete history taking.
• Thorough clinical examination.
• Body mass index (BMI) assessment.
• Quantitative muscle strength tests
• Functional grading
• Childhood Myositis Assessment Scale.
(B) Laboratory assessment:
All patients will be subjected to the following measurements:
• Serum creatine kinase levels (CK).
• Serum Lactate dehydrogenase levels
• Serum of Liver enzymes (SGOT& SGPT) levels.
(C) Electromyographic (EMG) assessment:
(D) Musculoskeletal ultrasound assessment
(E) Statistical analysis
- Kendall's manual muscle testing [ Time Frame: 24 months ]
Kendall's 0 -10 point scale measures strength of each muscle group score 0 is the weakest (worst) and 10 is the strongest (best). The following muscles were tested bilaterally: the biceps brachii muscle (BB), the forearm flexors (FF), the rectus femoris muscle (RF), the tibialis anterior muscle (TA)
- Childhood myositis assessment scale [ Time Frame: 24 months ]
Used to assess the severity of muscle involvement in children with dermatomyositis. The scores for the 14 items are summated to give a total score ranging from 0 (worst) to 52 (best)
- Serum creatine kinase (CK) levels [ Time Frame: 24 months ]
CK measured in U/L using ELISA
- Serum Lactate dehydrogenase (LDH) levels [ Time Frame: 24 months ]
CK measured in IU/L using ELISA
- Aspartate aminotransferase (AST) [ Time Frame: 24 MONTHS ]
AST measured in U/L using ELISA
- Alanine aminotransferase (ALT) [ Time Frame: 24 months ]
ALT measured in U/L using ELISA
- Motor unit potential (MUP) duration [ Time Frame: 24 months ]
Quantitative electromyography (QEMG) in the most affected rectus femoris and biceps brachii muscles will be performed and The motor unit potentials will be reviewed offline for the needle-detected EMG signals will be analyzed by the device software for the MUP duration measured in milliseconds.
- Motor unit peak-to-peak amplitude [ Time Frame: 24 months ]
Quantitative electromyography (QEMG) in the most affected rectus femoris and biceps brachii muscles will be performed and The motor unit potentials will be reviewed offline for the needle-detected EMG signals will be analyzed by the device software for the peak-to-peak amplitude measured in microvolt
- Motor unit area to amplitude ratio (AAR) [ Time Frame: 24 months ]
Quantitative electromyography (QEMG) in the most affected rectus femoris and biceps brachii muscles will be performed and The motor unit potentials will be reviewed offline for the needle-detected EMG signals will be analyzed by the device software for the motor unit AAR .
• Children with Duchenne muscular dystrophy (DMD). Diagnosis with DMD was established according to DMD diagnostic criteria (Jennekens et al., 1991).
• Children with juvenile dermatomyositis (JDM) according to Bohan and Peter diagnostic criteria ( (Bohan and Peter, 1975).
• Patients with age less than 2 years were excluded from the study due to inability to perform manual muscle testing and functional scales.
• If no final diagnosis could be established.
• The presence of a concomitant illness that may result in peripheral neuropathy or myopathy.
Quantitative muscle ultrasound detects disease progression in Duchenne muscular dystrophyObjective:We assessed changes in quantit...
Electrical Impedance Myography and Ultrasound as Biomarkers of Duchenne Muscular DystrophyResearchers at Children's Hospital Bosto...
Longitudinal functional and NMR assessment of upper limbs in Duchenne muscular dystrophyOBJECTIVE:To explore the value of nuclea...
Cardiac Magnetic Resonance in Children With Muscular DystrophyThis protocol will exploit novel state o...
Extracellular RNAs in Urine May Work as Biomarker for Duchenne and Myotonic Dystrophy PatientsExtracellular RNAs found in urine may be...
Large-scale serum protein biomarker discovery in Duchenne muscular dystrophySerum biomarkers in Duchenne muscular dy...
Santhera to present novel data highlighting the clinical relevance of peak expiratory flow as predictor of disease p...Santhera Pharmaceuticals announces that ...